Pressure to make new Lundbeck drug a success rests on Peter Anastasiou

The head of Lundbeck in the USA, Peter Anastasiou, has prepared the US organization for the launch of migraine drug Vyepti at record speed. It is Lundbeck's first new launch since 2015 - and it is a big task to bear.

Photo: Lundbeck/ PR

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try MedWatch for 14 days.

Get a trial subscription here.

Do you want a trial subscription with multiple users for yourself and your colleagues?

Read more about your options and find the contact information to our sales team here.

Related articles